204 related articles for article (PubMed ID: 26062933)
1. Biodistribution of the ¹⁸F-FPPRGD₂ PET radiopharmaceutical in cancer patients: an atlas of SUV measurements.
Minamimoto R; Jamali M; Barkhodari A; Mosci C; Mittra E; Shen B; Chin F; Gambhir SS; Iagaru A
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1850-8. PubMed ID: 26062933
[TBL] [Abstract][Full Text] [Related]
2. (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
Iagaru A; Mosci C; Shen B; Chin FT; Mittra E; Telli ML; Gambhir SS
Radiology; 2014 Nov; 273(2):549-59. PubMed ID: 25033190
[TBL] [Abstract][Full Text] [Related]
3. Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer.
Minamimoto R; Karam A; Jamali M; Barkhodari A; Gambhir SS; Dorigo O; Iagaru A
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1047-55. PubMed ID: 26611425
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT.
Iagaru A; Mosci C; Mittra E; Zaharchuk G; Fischbein N; Harsh G; Li G; Nagpal S; Recht L; Gambhir SS
Radiology; 2015 Nov; 277(2):497-506. PubMed ID: 25965900
[TBL] [Abstract][Full Text] [Related]
5. Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels.
Mittra ES; Goris ML; Iagaru AH; Kardan A; Burton L; Berganos R; Chang E; Liu S; Shen B; Chin FT; Chen X; Gambhir SS
Radiology; 2011 Jul; 260(1):182-91. PubMed ID: 21502381
[TBL] [Abstract][Full Text] [Related]
6.
Toriihara A; Duan H; Thompson HM; Park S; Hatami N; Baratto L; Fan AC; Iagaru A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1518-1523. PubMed ID: 30850872
[TBL] [Abstract][Full Text] [Related]
7. A pilot study imaging integrin αvβ3 with RGD PET/CT in suspected lung cancer patients.
Gao S; Wu H; Li W; Zhao S; Teng X; Lu H; Hu X; Wang S; Yu J; Yuan S
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2029-37. PubMed ID: 26153145
[TBL] [Abstract][Full Text] [Related]
8. Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI.
Heusch P; Buchbender C; Beiderwellen K; Nensa F; Hartung-Knemeyer V; Lauenstein TC; Bockisch A; Forsting M; Antoch G; Heusner TA
Eur J Radiol; 2013 May; 82(5):870-6. PubMed ID: 23394765
[TBL] [Abstract][Full Text] [Related]
9. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
[TBL] [Abstract][Full Text] [Related]
10. Comparison of standardized uptake values in normal structures between PET/CT and PET/MRI in an oncology patient population.
Kershah S; Partovi S; Traughber BJ; Muzic RF; Schluchter MD; O'Donnell JK; Faulhaber P
Mol Imaging Biol; 2013 Dec; 15(6):776-85. PubMed ID: 23632951
[TBL] [Abstract][Full Text] [Related]
11. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy.
Sun X; Yan Y; Liu S; Cao Q; Yang M; Neamati N; Shen B; Niu G; Chen X
J Nucl Med; 2011 Jan; 52(1):140-6. PubMed ID: 21149494
[TBL] [Abstract][Full Text] [Related]
12. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG.
Beer AJ; Lorenzen S; Metz S; Herrmann K; Watzlowik P; Wester HJ; Peschel C; Lordick F; Schwaiger M
J Nucl Med; 2008 Jan; 49(1):22-9. PubMed ID: 18077538
[TBL] [Abstract][Full Text] [Related]
13. Semiquantitative Assessment of
Minamimoto R; Xu G; Jamali M; Holley D; Barkhodari A; Zaharchuk G; Iagaru A
AJR Am J Roentgenol; 2017 Nov; 209(5):1136-1142. PubMed ID: 28777652
[TBL] [Abstract][Full Text] [Related]
14. PET-Based Human Dosimetry of the Dimeric αvβ3 Integrin Ligand 68Ga-DOTA-E-[c(RGDfK)]2, a Potential Tracer for Imaging Tumor Angiogenesis.
López-Rodríguez V; Galindo-Sarco C; García-Pérez FO; Ferro-Flores G; Arrieta O; Ávila-Rodríguez MA
J Nucl Med; 2016 Mar; 57(3):404-9. PubMed ID: 26585063
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Physiologic (18)F FSPG Uptake in Healthy Volunteers.
Mosci C; Kumar M; Smolarz K; Koglin N; Stephens AW; Schwaiger M; Gambhir SS; Mittra ES
Radiology; 2016 Jun; 279(3):898-905. PubMed ID: 26785040
[TBL] [Abstract][Full Text] [Related]
16. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
17. Semiquantitative Analysis of the Biodistribution of the Combined ¹⁸F-NaF and ¹⁸F-FDG Administration for PET/CT Imaging.
Minamimoto R; Mosci C; Jamali M; Barkhodari A; Habte F; Jackson T; Mittra E; Gambhir SS; Iagaru A
J Nucl Med; 2015 May; 56(5):688-94. PubMed ID: 25840978
[TBL] [Abstract][Full Text] [Related]
18. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP
AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485
[TBL] [Abstract][Full Text] [Related]
19. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
20. Can an ¹⁸F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma?
Zhang H; Liu N; Gao S; Hu X; Zhao W; Tao R; Chen Z; Zheng J; Sun X; Xu L; Li W; Yu J; Yuan S
J Nucl Med; 2016 Apr; 57(4):524-9. PubMed ID: 26514171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]